Basic Provigil Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In Canada (English): Not specified
• ATC Code: A10BA02
• Forms & Dosages: Film-coated tablets 500 mg, 850 mg, 1000 mg; prolonged-release tablets 500 mg, 750 mg, 1000 mg; oral solution 500 mg/5 ml, 100 mg/ml; powder (rare) for compounding
• Manufacturers In Canada (English): Not specified
• Registration Status In Canada (English): Not specified
• OTC / Rx Classification: Prescription (Rx)

Latest Research Highlights (Canadian & International: 2022–2025)

Since 2022 multiple randomized controlled trials and systematic reviews internationally reaffirm that modafinil improves excessive daytime sleepiness (EDS) in narcolepsy and shift-work sleep disorder with small-to-moderate effect sizes.

Safety signals in these trials have been generally mild-to-moderate, commonly including headache, insomnia and nausea, with rare reports of severe cutaneous or psychiatric reactions.

Canadian sleep-centre cohort analyses from 2022–2024 report clinical benefit in patients with refractory EDS who had limited response to stimulants or behavioural measures.

Pilot trials exploring modafinil for long-COVID fatigue produced mixed results, with some studies showing improvement on fatigue scales but inconsistent gains in objective functional measures.

Ongoing Canadian investigator-initiated trials (registered provincially) are assessing modafinil for post-stroke and multiple sclerosis–related fatigue with recruitment and follow-up continuing through 2025.

Evidence is often short-term (8–12 weeks) and patients commonly consider wakefulness gains against side-effect trade-offs when deciding whether to remain on treatment.

Indigenous, elderly and comorbid cardiac or psychiatric populations are underrepresented in randomized trials, so prescribers should individualize risk–benefit conversations for these groups.

Key Trials (2022–2025)

• Randomized trials of modafinil vs placebo in narcolepsy showing moderate ESS reductions over 8–12 weeks.
• Shift-work sleep disorder RCTs demonstrating improved on-shift alertness and reduced lapses in vigilance testing.
• Systematic reviews pooling small trials that report consistent daytime-sleepiness benefit but heterogeneity in functional outcomes.
• Pilot long-COVID fatigue trials with mixed fatigue-scale improvements and inconsistent return-to-work outcomes.
• Canadian sleep-centre cohort analyses showing benefit in refractory EDS with routine clinical follow-up.

Comparative Outcomes Table (Selected RCTs 2022–2025)

Where possible, discuss trial duration and follow-up expectations with patients because most data cover 8–12 weeks only.

Clinical Effectiveness In Canada

Canadian clinical practice mirrors international evidence: modafinil reduces EDS severity in narcolepsy and improves alertness for many shift-work patients.

Health Canada classifies modafinil as prescription-only and its approved indications include narcolepsy and shift-work sleep disorder in most jurisdictions.

Observational Canadian data show reductions in symptom scores and improved workplace functioning for many patients, though measurable functional outcomes vary by study.

Coverage across provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ is inconsistent and often requires prior authorization or specialist documentation.

Brand-name Provigil versus generic pricing affects uptake in provincial formularies, and many patients rely on private plans or manufacturer assistance when available.

Coverage Terms (Definition List)

• Prior Authorization: A formal approval process required by some provincial plans before coverage will be granted.
• Exceptional Access: Case-by-case reimbursement where standard listing criteria are not met but clinical need is demonstrated.
• Specialist Documentation: Referral or letter from a sleep specialist supporting the diagnosis and treatment rationale.

Clinicians should record a baseline Epworth Sleepiness Scale (ESS), titrate cautiously and arrange follow-up sleep assessments to document benefit and monitor harms.

Rural patients may face delays accessing sleep specialists, so community pharmacists at major chains and regional clinics provide critical counselling and follow-up support.

Indications & Expanded Uses (Approved Vs Off-Label)

Approved indications per major regulators include narcolepsy with EDS and shift-work sleep disorder, and many clinicians use modafinil adjunctively for residual sleepiness in obstructive sleep apnea.

Off-label uses explored through 2025 include long-COVID fatigue, multiple sclerosis fatigue, adjunctive ADHD therapy and selective cognitive impairment settings, but evidence is mixed and often short-duration.

In Canada, off-label prescribing is common but requires informed consent and clinical documentation, and provincial drug programs rarely reimburse off-label uses outside exceptional-access pathways.

When counselling patients, discuss realistic goals such as symptom reduction rather than cure, outline safety expectations and offer alternatives like sleep hygiene and cognitive behavioural therapy for insomnia.

Approved Vs Off-Label Uses

• Approved: Narcolepsy with EDS; Shift-Work Sleep Disorder; adjunctive use in residual obstructive sleep apnea sleepiness (practice varies).
• Off-Label (Explored): Long-COVID fatigue; multiple sclerosis fatigue; adjunctive ADHD therapy; selected cognitive impairment trials.

Level Of Evidence Summary

Reassess response at 4–12 weeks and document outcomes to support continued therapy and any coverage requests.

Composition & Brand Landscape (Active Ingredient, Brands, Generics)

Provigil is the brand name commonly used for modafinil in many markets.

In Canada the market includes brand and generic formulations when available, and tablet strengths commonly used internationally are 100 mg and 200 mg, though local supplies vary by manufacturer and distributor.

Generic competition typically lowers price where multiple suppliers provide modafinil tablets.

Data Highlights (Illustrative Product Metadata Format)

Patients should check the Drug Identification Number (DIN) on Health Canada labels and confirm the manufacturer if coverage requires a specific DIN.

Brand/Generic Table (Canadian Formulations — DIN Column For Local Verification)

Definition: INN is the International Nonproprietary Name; brand is the commercial name; DIN is the Canadian identifier printed on approved product labels.

Contraindications & Special Precautions (Canadian Focus)

Known hypersensitivity to modafinil is an absolute contraindication.

Uncontrolled hypertension, significant cardiac history and severe psychiatric illness (risk of mania or psychosis) are important precautions identified in trials and pharmacovigilance reports.

Pregnancy and lactation warrant caution due to limited data.

Rare but serious dermatologic reactions such as Stevens–Johnson syndrome have been reported and require immediate discontinuation if suspected.

Absolute And Relative Contraindications

• Absolute: Known hypersensitivity to modafinil.
• Relative / Caution: Uncontrolled hypertension; significant cardiac disease; severe psychiatric illness; pregnancy/lactation; severe hepatic impairment.

High-risk Canadian groups include the elderly with polypharmacy, patients with substance-use histories and Indigenous or remote-dwelling patients who may lack close follow-up.

Comorbid liver impairment affects metabolism and may require dose adjustment or specialist review.

Health Canada advisories recommend baseline cardiovascular and psychiatric screening and documentation of a monitoring plan.

Dosage Guidelines (Standard Canadian Dosing & Adjustments)

For narcolepsy, international guidance typically starts modafinil at 100–200 mg once daily in the morning, with titration based on response and tolerability.

For shift-work sleep disorder, 200 mg taken before the start of the work shift is a commonly used regimen.

Once-daily morning dosing is supported by evidence to reduce insomnia risk when possible.

Starting Doses By Indication

• Narcolepsy: 100–200 mg once daily in the morning, titrate as needed.
• Shift-Work Sleep Disorder: 200 mg approximately 1 hour before shift.
• Off-Label / Fatigue Trials: Doses varied in trials; follow trial protocols or specialist advice.

Dose Adjustments & Special Populations

For patients on interacting drugs such as hormonal contraceptives, counsel on reduced contraceptive efficacy and discuss alternatives or additional precautions.

Monitor blood pressure and mood within 2–4 weeks of starting and discontinue if severe adverse events occur.

Interactions Overview (Drugs, Foods, Lifestyle)

Modafinil is a moderate inducer of CYP3A4 and can reduce the effectiveness of hormonal contraceptives.

Modafinil may alter levels of some antidepressants, antiepileptics and anticoagulants, so clinicians and pharmacists should check for important interactions at prescribing and dispensing.

Alcohol and cannabis can worsen insomnia and increase psychiatric risk, which may reduce tolerability of wakefulness agents.

Major Drug Interactions

• Hormonal contraception: reduced efficacy reported; use barrier methods or alternative contraception while on modafinil unless otherwise advised.
• CYP3A4 substrates: monitor and adjust doses of sensitive medications as needed.
• Antiepileptics and some antidepressants: levels may be affected; therapeutic monitoring recommended.

Interaction Severity And Monitoring

Pharmacists in community chains should flag interactions at dispensing and provide bilingual counselling where required, especially in Quebec.

Cultural Perceptions & Patient Habits (Canada-Specific)

Many Canadian patients value symptom control but express concern about stigma associated with stimulant-like medicines and workplace disclosure.

Off-label cognitive-enhancement use is debated in universities and workplaces and raises ethical questions among clinicians and patients.

Urban patients generally access sleep specialists faster, while rural and Indigenous communities face longer wait times and limited sleep-lab availability.

Bilingual labelling and counselling in English and French are often requested in Quebec and at federal institutions.

Patient Concerns

• Stigma and workplace disclosure.
• Fear of dependence or abuse despite modafinil's lower abuse profile versus amphetamines.
• Access barriers in rural and Indigenous communities.

Shared decision-making, clear written information in English and French and community pharmacy follow-up help bridge access and cultural gaps.

Availability & Pricing Patterns (Canadian Pharmacies & Cross-Border Notes)

Brand Provigil availability varies across Canada and generic entrants increase supply where approved.

Pricing differences between private pay and provincial formularies create access gaps for some patients.

Cross-border price comparisons show lower single-fill prices in the United States in some cases, but importation rules and prescription requirements complicate self-importation for Canadian residents.

Major pharmacy chains and regional pharmacies dispense modafinil with a valid prescription, and online Canadian pharmacies require a DIN and a valid prescription.

In our online pharmacy, provigil is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Estimated Retail Cost Comparison (Illustrative)

Coverage Steps (Practical)

• Check provincial formulary listing and DIN requirements.
• Obtain specialist documentation if required for prior authorization.
• Ask pharmacists about manufacturer coupons, generic substitution and assistance with prior-authorization forms.

Comparable Medicines And Preferences (Alternatives In Canada)

Alternatives to modafinil for excessive daytime sleepiness include methylphenidate, amphetamine salts and newer wakefulness agents such as solriamfetol where available.

Comparative trials suggest modafinil often has a favourable tolerability profile compared with amphetamines, though stimulants may be more effective for some patients.

Formulary listings and reimbursement differ across provinces, and comorbidities like cardiac disease or substance use influence preferred choices.

Comparison Table: Common Wakefulness Options

Use the table as a checklist during shared decision-making, matching patient comorbidities and preferences to medicine profiles.

FAQ Section

• Is Provigil safe long-term?

  Long-term data show sustained benefit for many patients, but routine monitoring for blood pressure and psychiatric symptoms is recommended.

• Will it show on drug tests or employer testing?

  Modafinil can appear on some workplace screens; patients should disclose prescriptions to occupational health where required.

• Does it affect contraception?

  Evidence indicates reduced effectiveness of hormonal contraceptives; use barrier methods or alternative contraception while taking modafinil unless advised otherwise.

• Can I drive while taking it?

  Driving risk often decreases if daytime sleepiness improves, but avoid driving until response and side effects are assessed.

• How do I get it covered?

  Request specialist documentation and submit prior-authorization requests to provincial drug plans; pharmacists can assist with paperwork.

Guidelines For Proper Use (Pharmacist & Provincial Tips)

Sleep-medicine societies recommend baseline assessment including ESS, cardiovascular and psychiatric history before starting modafinil.

Start at a low dose, reassess at 4–12 weeks and monitor for adverse effects and interactions.

Pharmacists should perform medication reconciliation, counsel on interactions and provide clear storage and safety instructions.

Dispensing Checklist For Pharmacists

• Verify DIN and valid prescription.
• Confirm diagnosis and baseline ESS where available.
• Counsel on dose timing (morning), missed doses and signs of rash or psychiatric change.
• Advise on contraception interactions and recommend barrier methods if applicable.
• Arrange follow-up contact within 2–4 weeks, especially for high-risk patients.

Pharmacist Tasks Mapped To Provincial Programs

Document counselling and monitoring in the patient record to support continuity of care and exceptional-access requests if required.

Delivery Across Canada (English)